NCT00583830

A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

A Phase 2, Randomized, Multi-Center, Open-Label Study to Evaluate the Efficacy and Safety of Mapatumumab in Combination With Carboplatin and Paclitaxel as First Line Therapy in Subjects With Advanced Non-Small Cell Lung Cancer (NSCLC)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 111 (actual)
• Sponsor: Human Genome Sciences Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).

Conditions

• Non Small Cell Lung Cancer

Interventions

Type	Name	Description
BIOLOGICAL	Mapatumumab	30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
BIOLOGICAL	Mapatumumab	10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
DRUG	Paclitaxel	200 mg/m\^2 IV (in the vein), on day 1 of each 21 day cycle
DRUG	Carboplatin	AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle

Timeline

• Start date: 2007-01-01
• Primary completion: 2010-11-01
• Completion: 2011-02-01
• First posted: 2007-12-31
• Last updated: 2013-08-08

Locations

33 sites across 4 countries: United States, Germany, Hungary, Romania